These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 18727068

  • 1. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A, Gillis D, Lewis I.
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [Abstract] [Full Text] [Related]

  • 2. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    MRD-AML-BFM Study GroupDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. langebrake.claudia@mh-hannover.de, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D.
    J Clin Oncol; 2006 Aug 01; 24(22):3686-92. PubMed ID: 16877738
    [Abstract] [Full Text] [Related]

  • 3. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A.
    J Clin Oncol; 2008 Oct 20; 26(30):4944-51. PubMed ID: 18606980
    [Abstract] [Full Text] [Related]

  • 4. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun 20; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

  • 5. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L, D'Arena G, Zini G, Cascavilla N.
    Leuk Res; 2012 Apr 20; 36(4):401-6. PubMed ID: 22196957
    [Abstract] [Full Text] [Related]

  • 6. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A, Gillis D, Lewis I.
    Am J Clin Pathol; 2009 Jan 20; 131(1):16-26. PubMed ID: 19095561
    [Abstract] [Full Text] [Related]

  • 7. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A, Gillis D, Hissaria P, Lewis I.
    Am J Clin Pathol; 2008 Jun 20; 129(6):934-45. PubMed ID: 18480011
    [Abstract] [Full Text] [Related]

  • 8. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
    Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A.
    Leukemia; 2006 Oct 20; 20(10):1783-9. PubMed ID: 16838027
    [Abstract] [Full Text] [Related]

  • 9. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.
    J Clin Oncol; 2013 Nov 01; 31(31):3889-97. PubMed ID: 24062400
    [Abstract] [Full Text] [Related]

  • 10. [Detection of minimal residual disease in patients with acute myeloid leukemia].
    Gal'tseva IV, Savchenko VG, Kulikov SM, Parovichnikova EN, Miterev GIu, Maslova ER, Isaev VG.
    Ter Arkh; 2003 Nov 01; 75(7):8-14. PubMed ID: 12934474
    [Abstract] [Full Text] [Related]

  • 11. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D.
    J Clin Oncol; 2009 Nov 01; 27(31):5195-201. PubMed ID: 19752335
    [Abstract] [Full Text] [Related]

  • 12. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR, Wang H, Chang Y, Cheng YF, Fu JY, Zhang LP, Liu GL, Chen SS.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun 01; 26(6):327-31. PubMed ID: 16185473
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W, Schoch C, Haferlach T, Schnittger S.
    Crit Rev Oncol Hematol; 2005 Nov 01; 56(2):283-309. PubMed ID: 16213150
    [Abstract] [Full Text] [Related]

  • 14. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H.
    Eur J Haematol; 2004 Feb 01; 72(2):89-106. PubMed ID: 14962246
    [Abstract] [Full Text] [Related]

  • 15. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 16. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH.
    J Clin Oncol; 2015 Apr 10; 33(11):1258-64. PubMed ID: 25732155
    [Abstract] [Full Text] [Related]

  • 17. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T, Babusíková O.
    Neoplasma; 2006 Apr 10; 53(6):500-6. PubMed ID: 17167719
    [Abstract] [Full Text] [Related]

  • 18. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
    Wongprajun S, Auewarakul CU.
    J Med Assoc Thai; 2010 Jan 10; 93 Suppl 1():S157-64. PubMed ID: 20364570
    [Abstract] [Full Text] [Related]

  • 19. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T, Stevulova L, Kovarikova A, Babusikova O.
    Neoplasma; 2007 Jan 10; 54(6):471-7. PubMed ID: 17949229
    [Abstract] [Full Text] [Related]

  • 20. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.
    Rossi G, Minervini MM, Melillo L, di Nardo F, de Waure C, Scalzulli PR, Perla G, Valente D, Sinisi N, Cascavilla N.
    Ann Hematol; 2014 Jul 10; 93(7):1149-57. PubMed ID: 24554303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.